Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
Nabriva Therapeutics (NBRV) reported Q3 2022 revenue of $9.2 million, up from $8.9 million in Q3 2021, driven by increased product sales of SIVEXTRO. The company is shifting its focus toward SIVEXTRO commercialization to extend its cash runway, which is now projected into Q1 2023. Nabriva took measures to reduce costs by approximately 40% in staff and suspended early-stage R&D activities. The net loss for Q3 2022 was $11.5 million, a slight increase from $10.7 million in Q3 2021. Nabriva engaged Torreya Capital for strategic advisory support.
- Q3 2022 revenue of $9.2 million, a $0.3 million increase from Q3 2021.
- Continued prescription demand growth for SIVEXTRO.
- Cash runway extended into Q1 2023.
- Net loss increased to $11.5 million in Q3 2022 from $10.7 million in Q3 2021.
- Suspension of early-stage R&D activities may hinder long-term growth.
- Total costs of revenue increased by $4.3 million for nine months ending September 30, 2022.
- Shifted Focus to SIVEXTRO to Enable Cost Cutting -
- Cash Runway Extended into Q1 2023 -
- Q3 2022 Total Revenue of
- Engaged Torreya Capital As Strategic Advisor -
- Conference call today at 4:30 p.m. Eastern Time -
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced it has pivoted its strategic focus towards commercialization efforts, primarily focused on SIVEXTRO, to extend its cash runway, while exploring strategic options. Nabriva also issued financial results for the three months ended September 30, 2022.
“Given the pressures of the macro environment, we believe building on our commercial success with SIVEXTRO, as demonstrated by the continued prescription demand growth, is the most efficient and effective way to extend our cash runway and preserve optionality and value for our shareholders,” said Ted Schroeder, Nabriva’s CEO.
Mr. Schroeder continued, “Aligned with the shift in our strategic focus, we have suspended early-stage research and development activities and reduced global headcount by approximately
Torreya Capital will advise Nabriva on its exploration of a range of strategic options, which could include the potential in-licensing or out-licensing of commercial stage assets. This process may not result in any transaction, and the Company does not intend to disclose additional details unless and until it has entered into a specific transaction.
CORPORATE AND DEVELOPMENT UPDATES
- On August 11, 2022, we announced the completion of enrollment in our Phase 1 clinical trial of XENLETA as potential treatment of resistant bacterial infections in patients with Cystic Fibrosis. The Phase 1 trial is an open label, randomized, crossover study to assess the safety and pharmacokinetics following singled doses of oral and intravenous XENLETA in adult patients with Cystic Fibrosis.
- On September 15, 2022, we announced a 1-for-25 reverse stock split which was necessary for us to regain compliance with the minimum
$1.00 per share requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (Bid Price Rule). We were notified by Nasdaq on September 30, 2022 that we had regained compliance with the Bid Price Rule.
FINANCIAL RESULTS
Three Months Ended September 30, 2022 and 2021
- Revenues for the three months ended September 30, 2022 were
$9.2 million compared to$8.9 million for the three months ended September 30, 2021. The$0.3 million increase was driven by an increase in product revenue, net, offset by a decrease in collaboration revenues. - Cost of revenues for the three months ended September 30, 2022 was
$4.4 million compared to$4.2 million for the three months ended September 30, 2021. The$0.2 million increase was primarily due to SIVEXTRO costs, which were not incurred prior to the launch of our own SIVEXTRO New Drug Code (NDC) in April 2021. - Research and development expenses for the three months ended September 30, 2022 were
$4.0 million compared to$3.2 million for the three months ended September 30, 2021. The$0.8 million increase was primarily due to a$0.5 million increase in consulting fees and a$0.4 million increase in research materials and purchased services driven by our Phase 1 trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA for the treatment of resistant bacterial infections in adult patients with cystic fibrosis. - Selling, general and administrative expenses for the three months ended September 30, 2022 were
$11.9 million compared to$12.3 million for the three months ended September 30, 2021. The$0.3 million decrease was driven by a decrease in personnel costs and a decrease in stock-based compensation expenses. - Net loss increased by
$0.9 million from a$10.7 million net loss for the three months ended September 30, 2021 to a$11.5 million net loss for the three months ended September 30, 2022.
Nine Months Ended September 30, 2022 and 2021
- Revenues for the nine months ended September 30, 2022 were
$26.4 million compared to$19.6 million for the nine months ended September 30, 2021. The$6.7 million increase was primarily due to a$8.6 million increase in SIVEXTRO product revenue, net, partly offset by a$2.5 million decrease in collaboration revenues. - Cost of revenues for the nine months ended September 30, 2022 was
$12.2 million compared to$7.9 million for the nine months ended September 30, 2021. The$4.3 million increase was primarily due to SIVEXTRO costs, which were not incurred prior to the launch of our own SIVEXTRO NDC on April 12, 2021. - Research and development expenses for the nine months ended September 30, 2022 were
$11.6 million compared to$10.2 million for the nine months ended September 30, 2021. The$1.4 million increase was primarily due to a$0.9 million increase in research materials and purchased services driven by our Phase 1 trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA for the treatment of resistant bacterial infections in adult patients with cystic fibrosis, and a$0.4 million increase in advisory and external consultancy expenses. - Selling, general and administrative expenses for the nine months ended September 30, 2022 were
$35.7 million compared to$37.2 million for the nine months ended September 30, 2021. The$1.5 million decrease was primarily due to a decrease in advisory and external consultancy expenses. - Net loss decreased by
$2.0 million from a$36.4 million net loss for the nine months ended September 30, 2021 to a$34.4 million net loss for the nine months ended September 30, 2022. - As of September 30, 2022, Nabriva had
$14.8 million in cash, cash equivalents and restricted cash. Based on its current operating plans, Nabriva expects that its existing cash resources will be sufficient to enable it to fund its operating expenses, debt service obligations and capital expenditure requirements into the first quarter of 2023.
Please refer to our Annual Report on Forms 10-K for the fiscal year ended December 31, 2021 and our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 filed with the U.S. Securities and Exchange Commission, for additional information regarding the Company’s business and financial results.
Company to Host Conference Call
Nabriva’s management will host a conference call today at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is (833) 634-2311 for domestic participants and (412) 902-4177 for international participants and ask to join the “Nabriva Therapeutics Conference Call.” A live webcast of the conference call can be accessed through the “Investors” tab on the Nabriva Therapeutics website at www.nabriva.com. A replay will be available on this website shortly after conclusion of the event for 90 days.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
About SIVEXTRO
SIVEXTRO (tedizolid phosphate) was approved by the U.S. Food and Drug Administration in 2014. It is indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius and Streptococcus constellatus), and Enterococcus faecalis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
About XENLETA
XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. XENLETA’s binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes. Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP. In these trials, XENLETA was compared with moxifloxacin and in one trial, moxifloxacin with and without linezolid. Patients who received XENLETA had similar rates of efficacy as those taking moxifloxacin alone or moxifloxacin plus linezolid. The most common adverse reactions associated with XENLETA included diarrhea, nausea, reactions at the injection site, elevated liver enzymes, and vomiting. For more information, please visit www.XENLETA.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about its ability to successfully commercialize XENLETA for the treatment of CABP, including the managed care coverage for XENLETA, the distribution and promotion of SIVEXTRO for the treatment of ABSSSI, the development of CONTEPO for Complicated Urinary Tract Infections (cUTI), the clinical utility of XENLETA for CABP and Cystic Fibrosis, SIVEXTRO for ABSSSI and of CONTEPO for cUTI, the impact of macro events on sales of SIVEXTRO and XENLETA, plans for and timing of the review of regulatory filings for XENLETA and CONTEPO, efforts to bring CONTEPO to market, the market opportunity for and the potential market acceptance of XENLETA for CABP, SIVEXTRO for ABSSSI and CONTEPO for cUTI, the prospects for future sales of SIVEXTRO, the development of XENLETA and CONTEPO for additional indications, plans to pursue research and development of other product candidates, plans to pursue business development initiatives, expectations regarding the impact of the interruptions resulting from COVID-19 on its business, the sufficiency of Nabriva Therapeutics’ existing cash resources and its expectations regarding anticipated revenues from product sales and how far into the future its existing cash resources will fund its ongoing operations and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics’ ability to successfully execute its commercialization plans for SIVEXTRO and whether market demand for SIVEXTRO is consistent with its expectations, Nabriva Therapeutics’ ability to build and maintain a sales force for SIVEXTRO, the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of CONTEPO for the treatment of cUTI, the extent of business interruptions resulting from the infection causing the COVID-19 outbreak or similar public health crises, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments will cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.
CONTACT:
For Investors and Media
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com
Consolidated Balance Sheets (unaudited)
| As of | As of | |||||||
| (in thousands, except share data) | September 30, 2022 | December 31, 2021 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 14,647 | $ | 47,659 | ||||
| Restricted cash | 121 | 175 | ||||||
| Short-term investments | — | 16 | ||||||
| Accounts receivable, net and other receivables | 12,388 | 12,751 | ||||||
| Inventory | 17,333 | 14,509 | ||||||
| Prepaid expenses | 3,074 | 5,155 | ||||||
| Total current assets | 47,563 | 80,265 | ||||||
| Property and equipment, net | 293 | 233 | ||||||
| Intangible assets, net | 7 | 31 | ||||||
| Other non-current assets | 377 | 380 | ||||||
| Total assets | $ | 48,240 | $ | 80,909 | ||||
| Liabilities and stockholders´ equity | ||||||||
| Current liabilities: | ||||||||
| Current portion of long-term debt | $ | 5,733 | $ | 3,765 | ||||
| Accounts payable | 3,895 | 4,372 | ||||||
| Accrued expense and other current liabilities | 12,012 | 13,829 | ||||||
| Deferred revenue | — | 374 | ||||||
| Total current liabilities | 21,640 | 22,340 | ||||||
| Non-current liabilities: | ||||||||
| Long-term debt | 399 | 4,265 | ||||||
| Other non-current liabilities | 578 | 954 | ||||||
| Total non-current liabilities | 977 | 5,219 | ||||||
| Total liabilities | 22,617 | 27,559 | ||||||
| Stockholders’ Equity: | ||||||||
| Ordinary shares, nominal value | 30 | 23 | ||||||
| Preferred shares, par value | — | — | ||||||
| Additional paid in capital | 655,649 | 648,976 | ||||||
| Accumulated other comprehensive income | 27 | 27 | ||||||
| Accumulated deficit | (630,083 | ) | (595,676 | ) | ||||
| Total stockholders’ equity | 25,623 | 53,350 | ||||||
| Total liabilities and stockholders’ equity | $ | 48,240 | $ | 80,909 | ||||
Consolidated Statements of Operations (unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| (in thousands, except share and per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue, net | $ | 8,643 | $ | 7,858 | $ | 24,363 | $ | 14,928 | ||||||||
| Collaboration revenue | 141 | 562 | 866 | 3,377 | ||||||||||||
| Research premium and grant revenue | 369 | 442 | 1,135 | 1,329 | ||||||||||||
| Total revenues | 9,153 | 8,862 | 26,364 | 19,634 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenues | (4,416 | ) | (4,199 | ) | (12,232 | ) | (7,882 | ) | ||||||||
| Research and development expenses | (4,032 | ) | (3,221 | ) | (11,637 | ) | (10,239 | ) | ||||||||
| Selling, general and administrative expenses | (11,907 | ) | (12,256 | ) | (35,654 | ) | (37,157 | ) | ||||||||
| Total operating expenses | (20,355 | ) | (19,676 | ) | (59,523 | ) | (55,278 | ) | ||||||||
| Loss from operations | (11,202 | ) | (10,814 | ) | (33,159 | ) | (35,644 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Other income, net | 354 | 131 | 570 | 479 | ||||||||||||
| Interest expense, net | (146 | ) | (221 | ) | (559 | ) | (678 | ) | ||||||||
| Loss before income taxes | (10,994 | ) | (10,904 | ) | (33,148 | ) | (35,843 | ) | ||||||||
| Income tax benefit (expense) | (520 | ) | 252 | (1,259 | ) | (544 | ) | |||||||||
| Net loss | $ | (11,514 | ) | $ | (10,652 | ) | $ | (34,407 | ) | $ | (36,387 | ) | ||||
| Loss per share | ||||||||||||||||
| Basic and diluted ($ per share) | $ | (4.21 | ) | $ | (5.27 | ) | $ | (13.55 | ) | $ | (23.17 | ) | ||||
| Weighted average number of shares: | ||||||||||||||||
| Basic and diluted | 2,732,749 | 2,021,070 | 2,539,408 | 1,570,389 | ||||||||||||
Condensed Consolidated Statements of Cash Flows (unaudited)
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| (in thousands) | 2022 | 2021 | ||||||
| Net cash provided by (used in): | ||||||||
| Operating activities | $ | (35,086 | ) | $ | (53,439 | ) | ||
| Investing activities | (256 | ) | (69 | ) | ||||
| Financing activities | 2,510 | 64,228 | ||||||
| Effects of exchange rate changes on the balance of cash held in foreign currencies | (234 | ) | (136 | ) | ||||
| Net increase (decrease) in cash and cash equivalents and restricted cash | (33,066 | ) | 10,584 | |||||
| Cash and cash equivalents and restricted cash at beginning of period | 47,834 | 41,590 | ||||||
| Cash and cash equivalents and restricted cash at end of period | $ | 14,768 | $ | 52,174 | ||||
FAQ
What were Nabriva's total revenues for Q3 2022?
How much did Nabriva's net loss increase in Q3 2022?
What is the future cash runway of Nabriva?
What cost-cutting measures has Nabriva implemented?
Who is advising Nabriva on strategic options?
